Clinical Trial

TriPRIL CAR T Cells in Multiple Myeloma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-08-08
notable Enrollment reduced: 18 -> 16 participants 2026-08-08
notable Primary completion pushed: 2026-03-31 -> 2028-02-24 2026-05-13
minor Completion moved earlier: 2028-03-31 -> 2028-02-24 2026-05-13
Trial Details
NCT Number NCT05020444
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Enrollment 16 participants
Start Date 2021-10-05
Primary Completion 2028-02-24 (estimated)
Study Completion 2028-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-07